Yahoo!
My Yahoo!
Mail
Sign In
[New User?
Sign Up
]
Finance Home
|
Help
Monday, November 23, 2009, 7:25PM AEST - The Australian Stockmarket is closed.
To create a watchlist or portfolio of shares,
Register
FINANCE HOME PAGE
INVESTING
FINANCE NEWS
PERSONAL FINANCE
SMALL BUSINESS
Enter symbol(s):
Symbol Lookup
|
Exchanges
Search News:
Ardea Biosciences, Inc. (RDEA)
On Nov 21:
13.68 USD
0.00 (0.00%)
MORE ON RDEA
Quotes
Summary
Options
Historical Prices
Charts
Basic Chart
Technical Chart
Technical Analysis
Detailed Data
News & Info
Headlines
Company Events
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Insider Trans.
Insider Roster
Financials
Income Statement
Balance Sheet
Cash Flow
Ardea Biosciences, Inc.
(NGM:RDEA) Delayed quote data
Last Trade:
13.68 USD
Trade Time:
Nov 21
Change:
0.00 (0.00%)
Prev Close:
13.68
Open:
N/A
Bid:
N/A
Ask:
N/A
1y Target Est:
25.25
Day's Range:
N/A - N/A
52wk Range:
6.29 - 21.35
Volume:
0
Avg Vol
(3m)
:
88,106.1
Market Cap:
251.92M
P/E
(ttm)
:
N/A
EPS
(ttm)
:
-2.14
Div & Yield:
N/A (N/A%)
1d
5d
3m
6m
1y
2y
5y
max
Add RDEA to Portfolio
Download Data
HEADLINES
ARDEA BIOSCIENCES, INC./DE Financials
EDGAR Online Financials
(Sat, Nov 14)
New Star Analyst Rankings for Ardea Biosciences, Inc.
StarMine
(Wed, Nov 11)
ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online
(Sat, Nov 7)
Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
PR Newswire
(Sat, Nov 7)
ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Regulation FD Disclosure
EDGAR Online
(Wed, Nov 4)
Ardea Biosciences to Present at Three Upcoming Investor Conferences
Business Wire
(Wed, Oct 28)
Ardea Presents Gout Data
Zacks.com
(Fri, Oct 23)
ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Regulation FD Disclosure
EDGAR Online
(Mon, Oct 19)
Ardea Biosciences Announces Additional Positive Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting
Business Wire
(Mon, Oct 19)
Ardea Biosciences to Present Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting
Business Wire
(Wed, Sep 30)
Ardea Biosciences to Present at Three Upcoming Investor Conferences
Business Wire
(Wed, Sep 16)
More Headlines for RDEA...
ANALYST
EPS Est (next year)
(Dec-09)
:
-1.59
EPS Est (in 2 years)
(Dec-10)
:
-2.12
Avg Rec (current)*:
1.4
PEG Ratio:
N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion
-
Estimates
BUSINESS SUMMARY
Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), cancer, and inflammatory diseases in the United States.
Full Company Profile
Add to Portfolio
Email to a Friend
Get
Summary
for Another Symbol:
Australia
New Zealand
US
----------------
Argentina
Austria
Brazil
Canada - Toronto
Canada - Vancouver
China - Shanghai
China - Shenzhen
Denmark
France
Germany XETRA
Germany - Berlin
Hong Kong
India - Bombay
India - National
Indonesia
Israel
Italy
Malaysia
Mexico
Netherlands
Norway
Singapore
South Korea - Korea
South Korea - KOSDAQ
Spain
Sweden
Switzerland
Taiwan OTC
Taiwan
Thailand
United Kingdom
Symbol Lookup
Latest News
7 Indices